Concomitant potent and moderate CYP3A inducers (without a potent CYP3A inhibitor): 600mg twice daily. Children: <2yrs or <2kg: not recommended.

See Contraindications. Potentiated by CYP2C9 (eg, fluconazole, amiodarone) or strong or moderate CYP3A inhibitors (eg, ketoconazole, itraconazole, amprenavir, erythromycin, diltiazem); concomitant ...

CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA ...

Moderate CYP3A Inhibitors: When CALQUENCE is co-administered with a moderate CYP3A inhibitor, reduce CALQUENCE dose to 100 mg once daily. Strong CYP3A Inducers: Avoid co-administration with a ...

Dosage modifications are recommended for patients with hepatic impairment and those on concomitant moderate CYP3A inhibitors. The use of Journavx for moderate to severe pain has not been studied ...